NANOVIRICIDES INC stock forecast: down to 0.00 USD NNVC stock price prognosis


Forecast for Fri 07 Jul 2023 price 2.00

NANOVIRICIDES INC stock price forecast for further price development down to 0.00% (time horizon: 1 day) and price target of 0.00 USD. Short-term (time horizon: 2 weeks) NANOVIRICIDES INC share price prediction for 2023-07-07 with daily closed price projections

Key Facts

Symbol NNVC 

ISIN US6300873022 

CUSIP 630087302

Currency USD

Category Services-Commercial Physical & Biological Research

Forecast price change %

Finance numbers

Earnings per share -2.39

On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.

Summerized Form 10-K with GPT-2

Our Website is located at The Company has developed several anti-coronavirus drug candidates. Also it was found that SARS-CoV antibodies were cross-reacting with SARS-CoV-2. & The symptoms are generally less severe than SARS-CoV-2 but are similar. The nanoviricide is designed to protect the payload from metabolism in circulation. This increase may lead to increased effectiveness if there are no adverse effects. As of June 30, 2020, the Company has drawn down $1.1 million on this loan. No warrants were issued in this Offering. Anil Diwan on Fox Business - 01/28/2020”. & This may be one of the reasons why many antiviral antibodies fail in the field use. Also, the virus-binding ligands are chemically attached to the polymer. Expansion to additional indications is likely, as we perform further studies. Thus, HSV-1 primarily affects skin and mucous membranes causing “cold sores”. These studies established this drug candidate as a viable, effective potential drug. VZV is restricted to human tissue and only infects and replicates in human tissue. Intravenous acyclovir is also employed for treatment of various VZV indications. In some indications, the treatment has been continued for a year or so. At present we have not applied for any grants for these programs. & To date, the Company does not have any commercialized products. As such we assume that these datasets will be sufficient for filing an IND. & The current market size for anti-HIV treatments is in excess of $20 billion. There was no amendment to the license contract effected for this purpose. & The licenses can revert only in the case of a default by NanoViricides. Our ability to be competitive will depend on the success of this strategy. & The Company believes that our drugs by themselves may be eligible for patent protection. 2029(estimated) & Applications are in various prosecution stages. All of the resulting patents have substantially broad claims. & The facility became substantially operational at the end of December& 2015. Foscarnet is also used for VZV and ARN, but its toxicity is high. It is an influenza endonuclease inhibitor. The FDA may grant deferrals for submission of data, or full or partial waivers. We have never received approval for a product in the European Union to date. & Some of the PRVs have been “sold” for as much as $250M or so recently. & The Zika virus was added to this list recently. & This work-plan is expected to reduce certain risks of drug development. AR Biosystems,& Inc., Odessa, FL (non-GLP studies) & 2. In January& 2016, we signed an agreement with CORL. The H129 strain will be used in subsequent animal testing of nanoviricides. He is now Professor at Roseman University of Health Sciences College of Medicine, NV. A definitive agreement is expected to be negotiated between the parties thereafter. At June& 30, 2020, $561,580 was due to TheraCour. & Upon entry into the agreement additional deferrals ceased. The remaining deferred payments will become due upon IND filing. Website & Our website address is & There are specific FDA regulations that govern this process. & These may not take into account all of the activities involved for the development. Our relationship with TheraCour is discussed below. All other consultant/contractors would be more readily replaceable. We currently depend upon the efforts and abilities of our management team. Their patient benefit profiles

Summerized Form 10-K with GPT-2
Candlestick patterns

Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.

  • Meta analyst score 30.19/100
    • Good financial position.
    • Company revenue is not growing faster compared with the industry.

Institutional ownership list is based on filling form information

Holding name Date Amount
First Financial Bank - Trust Division 2022-09-30 10881
Asset Dedication, LLC 2022-12-31 1450
TFO-TDC, LLC 2022-12-31 12
Wharton Business Group, LLC 2023-03-31 15736
Asset Dedication, LLC 2023-03-31 1450

Fund ownership list is based on filling form information

Fund name Date Amount Profile
Fidelity Concord Street Trust 2023-02-28 8252 Long
Fidelity Concord Street Trust 2023-02-28 15314 Long
Fidelity Concord Street Trust 2023-02-28 82613 Long
iShares Trust 2022-12-31 1651 Long
Bridgeway Funds, Inc. 2022-12-30 94039 Long

Bollinger Bollinger Bands for NANOVIRICIDES INC can provide the information where the market is moving based on price information.

NANOVIRICIDES INC Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.

Converting prices to returns NANOVIRICIDES INC.

On-Balance Volume information for NANOVIRICIDES INC. On-Balance Volume information can be an indicator for bullish or bearish outcome.

Accumulation / Distribution (A/D) indicator information for NANOVIRICIDES INC. The indicator identify divergences between price and volume flow.

Aroon Oscillator information for NANOVIRICIDES INC. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.

Average Directional Index (ADX) information for NANOVIRICIDES INC. The index can be used to identify the strengh of a trend.

Moving Average Convergence Divergence (MACD) for NANOVIRICIDES INC. The indicator helps to predict trend direction and the momentum of the trend.

Stochastic Oscillator as momentum indicator for NANOVIRICIDES INC. The indicator is useful for identifying overbought and oversold levels.

Relative Strength Index (RSI) for NANOVIRICIDES INC. RSI is a momentum oscillator that measures the speed and change of price development. The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period. Primary usage of the indicator is to identify overbought or oversold signals. When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30 [ Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio ].

52W High 52W Low Market Cap

Similar shares



Figure below show the stock predictions.
Date Closing price Prediction was updated
2023-06-08 1.64 2023-05-13 17:18
2023-06-09 1.65 2023-05-13 17:18
2023-06-12 1.67 2023-05-13 17:18
2023-06-13 1.69 2023-05-13 17:18
2023-06-14 1.71 2023-05-13 17:18
2023-06-15 1.73 2023-05-13 17:18
2023-06-16 1.75 2023-05-13 17:18
2023-06-21 1.80 2023-05-13 17:18
2023-05-30 1.53 2023-05-13 17:18
2023-05-31 1.55 2023-05-13 17:18
2023-06-01 1.57 2023-05-13 17:18
2023-06-02 1.59 2023-05-13 17:18
2023-06-05 1.60 2023-05-13 17:18
2023-06-06 1.61 2023-05-13 17:18
2023-06-07 1.62 2023-05-13 17:18
2023-06-19 1.77 2023-05-13 17:18
2023-06-20 1.78 2023-05-13 17:18
2023-06-22 1.82 2023-05-13 17:18
2023-06-23 1.84 2023-05-13 17:18
2023-06-26 1.86 2023-05-13 17:18
2023-06-27 1.88 2023-05-13 17:18
2023-06-28 1.89 2023-05-13 17:18
2023-06-29 1.91 2023-05-13 17:18
2023-06-30 1.92 2023-05-13 17:18
2023-07-03 1.94 2023-05-13 17:18
2023-07-04 1.95 2023-05-13 17:18
2023-07-05 1.97 2023-05-13 17:18
2023-07-06 1.98 2023-05-13 17:18
2023-07-07 2.00 2023-05-13 17:18

The forecast (dashed curve) of the share price performance is based on historical data. Our forecast model is based on mathematical, statistical methods. The website offers price forecasts and analysis tools for equities and other securities, which are exclusively based on the prices of these securities in the past. Information about these prices is provided to us by third parties. Although we believe, If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and correct sequencing of this information. We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider any financial data or other data of such issuers with the exception of the past prices of the securities. Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or circumstances, that may be relevant for future security price flows. Investments require additional considerations. Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor or the tax implications an investment may have for the investor. Although we believe that our mathematical models are a tool to try to explore the possibility for future price development with the help of past performance, such developments are subject to a multitude of different influences. and therefore not really predictable. We cannot guarantee the success of any investment you make based on the information published here. This website is for information purposes only. All information and data on this website cannot be guaranteed to be accurate, accuracy, completeness and appropriateness - neither explicit nor implicit.